Leukemia drug repurposed to fight resistant lung cancer
NCT ID NCT06225427
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 38 times
Summary
This early-phase trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose cancer has stopped responding to other treatments. The main goals are to find the safest dose and understand side effects. Researchers hope the drug can overcome resistance that often develops to standard ALK-targeted therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
NOT_YET_RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Georgetown University
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.